Antibodies 2026

1 papers

Top Research Directions

The 2 research directions with Antibodies 2026 papers, ranked by paper count, next to 2023. Share is the fraction of the edition’s papers in the direction.

#Direction20262023Share 2026Share 20232023 rank
1Bridging the Preclinical Translation Gap in Nanomedicine10100.0%0.0%—
2Engineering High-Affinity Binders Through Iterative Library Selection10100.0%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Antibodies 2026 papers: a paper credits every institution named in its affiliations, once. 4 institutions share 1 credited papers.

#InstitutionPapersShare20232023 rank
1058t7w767 1100.0%0—
2Chinese Academy of Sciences 1100.0%0—
3Shanghai Institute of Materia Medica 1100.0%0—
4Shanghai Ocean University 1100.0%0—

Download all institutions as CSV

About this data

Papers. Antibodies 2026 lists 1 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2023 use shares, since the edition went from 1 to 1 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 1 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Antibodies 2026”, https://lacuna.tiptreesystems.com/venue/antibodies/2026.

Papers

Title
Camelid-Derived Nanobodies Targeting Human Epidermal Growth Factor Receptor: Screening, Expression, and Functional Validation